Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Plus Melphalan Prior to ASCT in Relapsed Multiple Myeloma
NCT01054196Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2010
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Started Aug 2010; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01054196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01054196.